URGN FY 2018 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-86.2% YoY

Gross Profit

-$675,000-59.8% margin

Operating Income

-$77M-6842.2% margin

Net Income

-$76M-6707.2% margin

EPS (Diluted)

$-4.80

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$38M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$104M

Total Liabilities

$13M

Stockholders' Equity

$90M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$8M	-86.2%
Gross Profit	-$675,000	$8M	-108.9%
Operating Income	-$77M	-$20M	-286.9%
Net Income	-$76M	-$20M	-278.3%